What you gain from Full Spectrum CBD is called the “entourage effect.” Studies have suggested that CBD is most effective when it’s combined with other cannabinoids. Each cannabinoid has its own properties and confers its own benefits. Working together, a synergy is created that boosts the healing properties of CBD. Full spectrum CBD does, however, bring with it the sticky issue of THC. The government regulates concentration levels of THC at 0.3 percent, an amount which results in minimal psychoactivity.
There’s a growing consensus that cannabis is a highly effective treatment for many kinds of neuropathic pain. A 2015 study published in Neurotherapeutics states, “Clinical studies largely affirm that neuropathic pain patients derive benefits from cannabinoid treatment.” But much of the human-based research (like this study) on CBD and nerve pain has centered around the efficacy of the FDA-approved medication Sativex, which includes both THC and CBD. Research on the best CBD for pain isolated from THC is still limited when it comes to neuropathic pain. There are exceptions, though:
If vaping or dabbing just isn’t your thing, there’s no better CBD product than Weller’s Coconut Bites. The small and discreet packaging fits neatly in your pocket, purse or gym bag and makes receiving calming CBD as simple as nibbling on a snack-sized Bite. Satisfyingly sweet and crunchy, they’re available in three delicious flavors: original, dark chocolate and caramel.
Our pick for Best Customer Experience is Fab CBD, a brand that offers high-quality CBD products at a reasonable price and provides additional perks for shoppers. The company’s CBD oil is available in four concentrations, ranging from 240mg to 1,500mg, which makes the oil suitable for those with light to moderate insomnia symptoms. The oil is available in natural, mint, and citrus flavors; prices range from 11 to 26 cents per mg, depending on the concentration. Fab CBD also offers edible gummies and a CBD topical oil.
Your product is not generally recognized as safe and effective for the referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in section 505(a) of the Act [21 U.S.C. § 355(a)]; see also section 301(d) of the Act [21 U.S.C. § 331(d)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.